IDO Believe in Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40100365.
- Also identified by DOI 10.1158/1078-0432.CCR-24-4264.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Indoleamine 2,3-dioxygenase 1 is central to immune downregulation. A recent phase I/II study tested the indoleamine 2,3-dioxygenase 1 inhibitor linrodostat with nivolumab ± ipilimumab in patients with advanced solid tumors. Although efficacy was not augmented, correlative analyses identified tryptophan 2,3 dioxygenase as a resistance mechanism; dual targeting may be necessary to realize improved response to PD-1 inhibition. See related article by Luke et al., p. 2134.
Medical subject headings
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Neoplasms
- Immunotherapy